骏码半导体(08490)发布公告，本集团预计于截至2025年6月30日止期间的本公司持有人应占亏损将约为 3040万港元(2024年同期取得本公司持有人应占溢利约220万港元)。由盈转亏的主要原因乃由于：部分 无形资产取得减值亏损;及集团的产品的营业额及毛利率于本期间取得下跌。 上述于本期间确认的减值亏损乃由于竞争激烈及于2025年上半年内整体消费意欲减弱，导致若干产品的 表现逊于预期。上述的减值为非现金开支，不会对本集团本期间的整体营运造成任何影响。本集团于本 期间的除利息、税项、厂房及设备折旧及无形资产摊销前溢利约为250万港元(截至2024年6月30日止： 约1870万港元)。 ...

Core Viewpoint - The company expects to incur a loss of no more than RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024, primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the US and Laos [1] Financial Performance - The anticipated loss for the first half of 2025 is attributed to the recognition of impairment and provisions for certain assets [1] - The actual amount of impairment and provisions will be subject to further assessment by the company [1] Business Outlook - The company believes that the impairments and provisions will not have a significant adverse impact on overall business operations and cash flow, as they are mainly one-time non-cash items [1] - Despite challenges posed by macroeconomic and industry conditions in the first half of 2025, the company remains confident in the long-term prospects for the industry and its growth due to solid industry fundamentals and supportive national policies [1] - The company is committed to improving clinical outcomes, patient care, and service quality, which reinforces its optimistic outlook for future growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告的全部或任何部份內容所產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited 錦 欣 生 殖 醫 療 集 團 有 限 公 司* 委任代理首席財務官 本公告由錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱為「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定義見上市規則） 刊發。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，根據對本集團截至二零二五年六月三十日止六個月（「二零二五年上半年」） 的未經審核綜合管理賬目（按照國際財務報告準則編製）的初步評估及董事會 目前可得資料，預期本集團將於二零二五年上半年錄得虧損不超過人民幣1,090 百萬元，而本集團於截至二零二四年六月三十日止六個月（「二零二四年上半年」） 則錄得純利約人民幣190百萬元。此虧損乃主要由於就有關本集團 ...

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, primarily focusing on a lawsuit that has led to a qualified audit opinion due to the complexity of the case and the potential financial implications [1][2]. Group 1: Financial Reporting and Audit - The company's 2024 financial statements received a qualified audit opinion due to a lawsuit involving a claim for the return of distributed profits amounting to 152 million yuan, which represents 116% of the company's net assets attributable to shareholders [1][2]. - The company believes the lawsuit qualifies as a post-balance sheet adjustment matter under accounting standards, but it does not meet the criteria for recognizing a provision for expected liabilities [6][11]. - The audit team conducted various procedures, including reviewing litigation documents and consulting with legal counsel, but could not obtain sufficient evidence to determine the impact on the financial statements [10][11]. Group 2: Legal Proceedings - The lawsuit initiated by the Shanghai Changjiang United Metal Trading Center has progressed through the courts, with the company filing jurisdictional objections that were ultimately rejected [7][8]. - The company is actively preparing for evidence exchange scheduled for June 13, 2025, but the hearing was canceled, and further notifications from the court are awaited [7][8]. - The potential impact of the lawsuit on the company's financial performance remains uncertain, and the company will handle it according to relevant accounting standards as the case progresses [8][11]. Group 3: Business Performance - The company reported a significant decline in revenue for 2024, with total revenue of 507 million yuan, a decrease of 41.19% year-on-year, primarily due to a drop in logistics and warehousing services [20][21]. - The logistics and warehousing service revenue fell by 48.56%, while product sales revenue increased by 41.04%, indicating a shift in business dynamics [20][21]. - The company experienced substantial fluctuations in quarterly revenue, with the first quarter significantly outperforming subsequent quarters due to adjustments in business operations [29][30]. Group 4: Asset Impairment - The company recognized an impairment loss of 20.1 million yuan on intangible assets related to vehicle licenses, reflecting a decrease in demand for its logistics services [12][20]. - The assessment of the recoverable amount of the licenses was conducted by an external valuation firm, which determined the impairment was adequately accounted for [18][20]. - The decline in the utilization rate of vehicle licenses and the overall market conditions contributed to the impairment recognition [15][20].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 盈利警告 及 業務更新 本公告由領航醫藥及生物科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a) 條及香港法例第571章《證券及期貨條例》第XIVA部項下的內幕信息條文（定義 見上市規則）作出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，基於 對本集團截至2025年3月31日止年度（「本年度」）未經審核綜合管理賬目的初步 審閱及董事會目前可得資料，預計本集團本年度將錄得淨虧損約5.5億港元至6 億港元，而對比截至2024年3月31日止年度 ...